In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

ACADIA Pharmaceuticals Inc.. Trade Record

NASDAQ:ACAD ACADIA Pharmaceuticals Inc. stock gains 6.16% Exit Feb 7, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ACAD Jan 23, 2019, priceSeries
About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
95.81
Entry Date
Jan 23, 2019
Entry Price
20.81
Sell Date
Feb 7, 2019
Sell Price
22.09
Net Gain
6.16%
Hold Time
11 Trading Days